Abemaciclib Granted FDA Approval for Advanced Breast Cancer

Share this content:
The FDA approved abemaciclib for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer that progresses after endocrine therapy.
The FDA approved abemaciclib for hormone receptor–positive, HER2-negative advanced or metastatic breast cancer that progresses after endocrine therapy.

The US Food and Drug Administration (FDA) approved abemaciclib for the treatment of adult patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer who have progressed after receiving endocrine therapy.1

Abemaciclib was approved to be administered concomitantly with fulvestrant, an endocrine therapy, if the cancer had grown despite endocrine therapy. It was also approved as monotherapy for patients previously treated with endocrine therapy and chemotherapy after metastasis.

The FDA based its approval on evidence from the phase 3 MONARCH 2 study (ClinicalTrials.gov Identifier: NCT02107703), for which researchers randomly assigned 669 patients with advanced breast cancer to receive abemaciclib 150 mg twice daily with fulvestrant or placebo with fulvestrant.

Patients in the abemaciclib arm had a median progression-free survival of 16.4 months compared with 9.3 months in the placebo arm (hazard ratio [HR], 0.553; 95% CI, 0.449-0.681; P < .001). Patients in the abemaciclib arm had an objective response rate of 48.1% (95% CI, 42.6%-53.6%) vs 21.3% (95% CI, 15.1%-27.6%) in the placebo arm.

The most frequently reported adverse events with abemaciclib include diarrhea, nausea, vomiting, abdominal pain, neutropenia, anemia, infection, headache, and fatigue.

Abemaciclib was previously granted Breakthrough Therapy Designation and Priority Review.

Reference

  1. FDA approves new treatment for certain advanced or metastatic breast cancers [news release]. Silver Spring, MD: US Food and Drug Administration; September 28, 2017. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm578071.htm. Accessed September 28th, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters